Telomir Pharmaceuticals Inc
For the period ended Dec 31, 2024. Filed Feb 4, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Feb 4, 2025
TELO$0.57-17.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Power of Attorney (included on signature page)
In accordance with the Exchange Act, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
| Person | Capacity | Date |
|---|---|---|
| /s/ Erez Aminov | Chief Executive Officer and Chairman | February 4, 2025 |
| Erez Aminov | (Principal Executive Officer) | |
| /s/ Michelle Yanez, MBA | Chief Financial Officer | February 4 , 2025 |
| Michelle Yanez, MBA | (Principal Financial Officer and Principal Accounting Officer) | |
| /s/ Dr. Craig Eagle | Director | February 4 , 2025 |
| Dr. Craig Eagle | ||
| /s/ Ned MacPherson. | Director | February 4 , 2025 |
| Ned MacPherson. | ||
| /s/ Matthew Pratt Whalen, CPA | Director | February 4 , 2025 |
| Matthew Pratt Whalen, CPA | ||
| /s/ Matthew P. Del Giudice | Director | February 4 , 2025 |
| Matthew P. Del Giudice | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.